AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Tevogen Bio Holdings Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG0133954Z7
6.53▼ 0.28 (-4.11%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
6.81
Day's Range
6.35 – 6.81
52-Week Range
0.14 – 12.03
Volume
39.4K
Avg Volume
9,665
Share Statistics
Shares Outstanding
Employees
18
Exchange
XNAS
Listed
2024-02-15
Share count as of August 10, 2026

Tevogen Bio Holdings Inc. Common Stock (TVGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Tevogen Bio Holdings Inc. Common Stock (TVGN)
What is Tevogen Bio Holdings Inc. Common Stock's Market Cap?
Tevogen Bio Holdings Inc. Common Stock's Market Cap is $42.5M, based on as-reported figures from SEC (XBRL) filings.
What is Tevogen Bio Holdings Inc. Common Stock's Net Income (TTM)?
Tevogen Bio Holdings Inc. Common Stock's Net Income (TTM) is -$21.6M, based on as-reported figures from SEC (XBRL) filings.
What is Tevogen Bio Holdings Inc. Common Stock's EBITDA?
Tevogen Bio Holdings Inc. Common Stock's EBITDA is -$21.3M, based on as-reported figures from SEC (XBRL) filings.
What is Tevogen Bio Holdings Inc. Common Stock's Diluted EPS (TTM)?
Tevogen Bio Holdings Inc. Common Stock's Diluted EPS (TTM) is -3.32, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TVGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Net Interest Income
Change in fair value of warrants
Net loss
Net Income to Common Shareholders——
Diluted Net Income Available to Common Shareholders
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—